Funding of drugs: do vaccines warrant a different approach?

The Lancet Infectious Diseases

Volumn 8, Issue 11, 2008, Pages 727-733

  Beutels, Philippe ^a,b   Scuffham, Paul A ^c   MacIntyre, C Raina ^d  

^a Vaccine and Infectious Disease Institute   (Belgium)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; MUMPS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ARTICLE; CHICKENPOX; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; FUNDING; GASTROENTERITIS; HEALTH CARE; HEALTH CARE SYSTEM; HERD IMMUNITY; HOSPITAL CARE; HUMAN; IMMUNOGENICITY; INCIDENCE; INFLUENZA; INFLUENZA VIRUS; MEDICAL CARE; PARENTAL BEHAVIOR; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; ROTAVIRUS; STREPTOCOCCUS PNEUMONIAE; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 54049154786     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70258-5     Document Type: Note

References (72)

1. Van Damme P., and Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 9 suppl 3 (1996) 8-15
2. Kimmel S. Vaccine adverse events: separating myth from reality. Am Fam Physician 66 (2002) 2113-2120
3. Philipson T. Economic epidemiology and infectious disease. In: Newhouse J., and Culyer T. (Eds). Handbook of health economics (2000), North-Holland, New York
4. Welte R., Trotter C.L., Edmunds W.J., Postma M.J., and Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 23 (2005) 855-874
5. Haug C.J. Human papillomavirus vaccination-reasons for caution. N Engl J Med 359 (2008) 861-862
6. Newall A.T., Brotherton J., Esser M., et al. The seroepidemiology of human papillomavirus infection in Australia. Clin Infect Dis 46 (2008) 1647-1655
7. Fine P.E. Herd immunity: history, theory, practice. Epidemiol Rev 15 (1994) 265-302
8. Brisson M., and Edmunds W. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 26 (2006) 434-446
9. Edmunds W.J., Medley G.F., and Nokes D.J. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 18 (1999) 3263-3282
10. Whitney C.G., Pilishvili T., Farley M.M., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 (2006) 1495-1502
11. Lieu T.A., Cochi S.L., Black S.B., et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271 (1994) 375-381
12. Halloran M.E., Cochi S.L., Lieu T.A., Wharton M., and Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 140 (1994) 81-104
13. Gangarosa E., Galazka A., Wolfe C., et al. Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 351 (1998) 356-361
14. Thompson K.M., and Tebbens R.J. Eradication versus control for poliomyelitis: an economic analysis. Lancet 369 (2007) 1363-1371
15. Salmon D.A., Teret S.P., MacIntyre C.R., Salisbury D., Burgess M.A., and Halsey N.A. Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future. Lancet 367 (2006) 436-442
16. McIntyre P., and Leask J. Improving uptake of MMR vaccine. BMJ 336 (2008) 729-730
17. Tucker A., Isaacs D., and Burgess M. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia. Aust N Z J Public Health 25 (2001) 411-416
18. Oostvogel P.M., van Wijngaarden J.K., van der Avoort H.G., et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 344 (1994) 665-670
19. Miller M.A., Sutter R.W., Strebel P.M., and Hadler S.C. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA 276 (1996) 967-971
20. Bonnet M.-C., and Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine (2008) 10.1016/j.vaccine.2008.07.026 published online Aug 3.
21. Beutels P., Edmunds W.J., and Smith R.D. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Econ (2008) 10.1002/hec.1339 published online Feb 1.
22. Sadique M.Z., Edmunds W.J., Smith R.D., et al. Precautionary behavior in response to perceived threat of pandemic influenza. Emerg Infect Dis 13 (2007) 1307-1313
23. Keogh-Brown M.R., and Smith R.D. The economic impact of SARS: how does the reality match the predictions?. Health Policy 88 (2008) 110-120
24. Plahte J. Tiered pricing of vaccines: a win-win-win situation, not a subsidy. Lancet Infect Dis 5 (2005) 58-63
25. Philipson T.J., and Jena A.B. Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs. Forum Health Econ Policy 9 2 (2006) a3. http://www.bepress.com/fhep/biomedical_research/3/ (accessed August 20, 2008).
26. Light D. Is G8 putting profits before the world's poorest children?. Lancet 370 (2007) 297-298
27. Thiry N., Beutels P., Van Damme P., and Van Doorslaer E. Economic evaluations of varicella vaccination programmes: review of the literature. Pharmacoeconomics 21 (2003) 13-38
28. Beutels P., and Viney R.C. Comments on the Prosser et al approach to value disease reduction in children. Pediatrics 114 (2004) 1375-1376
29. Griebsch I., Coast J., and Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 115 (2005) e600-e614
30. Prosser L.A., Ray G.T., O'Brien M., Kleinman K., Santoli J., and Lieu T.A. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. Pediatrics 113 (2004) 283-290
31. Brouwer C.N., Maillé R.A., Rovers M.M., et al. Effect of pneumococcal vaccination on quality of life in children with recurrent acute otitis media: a randomized, controlled trial. Pediatrics 115 (2005) 273-279
32. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2008 (in press).
33. Beutels P., Van Doorslaer E., Van Damme P., and Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2 (2003) 649-660
34. Brouwer W., Niessen L., Postma M., and Rutten F. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331 (2005) 446-448
35. Claxton K., Sculpher M., Culyer A., et al. Discounting and cost-effectiveness in NICE-stepping back to sort out a confusion. Health Econ 15 (2006) 1-4
36. Weinstein M., Siegel J., Gold M., Kamlet M., and Russell L. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
37. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee (PBAC): including major submissions involving economic analyses (2002), Commonwealth Department of Health and Ageing, Canberra
38. UK National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (2004), National Institute for Health and Clinical Excellence, London
39. Dutch Health Insurance Board. Guidelines for pharmacoeconomic research (2006), College voor Zorgverzekeringen, Amstelveen, Netherlands
40. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. (2006), Canadian Agency for Drugs and Technologies in Health, Ottawa
41. Grocott R., Schoeler R., Priest V., et al. Prescription for pharmacoeconomic analysis (2007), Pharmac, Wellington, NZ
42. US Management and Budget Office. Discount rates for cost-effectiveness analysis of federal programs. Fed Reg 73 (2008) 5599
43. National Institute for Clinical Excellence. Guidance for manufacturers and sponsors (2001), National Institute for Clinical Excellence, London
44. Metcalfe S., Brougham M., Moodie P., and Grocott R. PHARMAC responds to Richard Milne on discounting health benefits and costs. N Z Med J 118 (2005) U1600
45. PHARMAC. A prescription for pharmacoeconomic analysis (2004), Pharmaceutical Management Agency, Wellington, New Zealand
46. Bleichrodt H., and Gafni A. Time preference, the discounted utility model and health. J Health Econ 15 (1996) 49-66
47. Loewenstein G., and Prelec D. Anomalies in intertemporal choice: evidence and an interpretation. Q J Econ 107 (1992) 573
48. Marglin S.A. The social rate of discount and the optimal rate of investment. Q J Econ 77 (1963) 95-111
49. Cairns J.A., and Van der Pol M.M. Saving future lives. A comparison of three discounting models. Health Econ 6 (1997) 341-350
50. Harvey C. Proportional discounting of future costs and benefits. Math Operations Res 20 (1995) 381-399
51. Bos J.M., Beutels P., Annemans L., and Postma M.J. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 22 (2004) 1171-1179
52. Baumol W.J. Social rate of discount. Am Econ Rev 58 (1968) 788-802
53. Bishai D., Koenig M., and Ali Khan M. Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ 12 (2003) 415-419
54. Panagiotopoulos T., and Georgakopoulou T. Epidemiology of rubella and congenital rubella syndrome in Greece, 1994-2003. Euro Surveill 9 (2004) 17-19
55. Jit M., Pebody R., Chen M., Andrews N., and Edmunds W.J. Estimating the number of deaths with rotavirus as a cause in England and Wales. Hum Vaccin 3 (2007) 23-26
56. Jit M., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 25 (2007) 3971-3979
57. Newall A.T., Beutels P., Macartney K., Wood J., and MacIntyre R. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 25 (2007) 8851-8860
58. Widdowson M.A., Meltzer M.I., Zhang X., Bresee J.S., Parashar U.D., and Glass R.I. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 119 (2007) 684-697
59. Newall A.T., Beutels P., Wood J.G., Edmunds W.J., and MacIntyre C.R. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7 (2007) 289-296
60. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 (2007) 5399-5408
61. Dasbach E., Insinga R., and Elbasha E. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 115 (2008) 947-956
62. Van de Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165 (2007) 762-775
63. Brisson M., and Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 88 (2003) 862-869
64. Oxman M.N., Levin M.J., Johnson G.R., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
65. Edmunds W.J., Brisson M., and Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19 (2001) 3076-3090
66. Thiry N., Beutels P., Tancredi F., et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 22 (2004) 3546-3562
67. Allison M.A., Daley M.F., Crane L.A., et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 149 (2006) 755-762
68. Coleman M.S., Washington M.L., Orenstein W.A., Gazmararian J.A., and Prill M.M. Interdisciplinary epidemiologic and economic research needed to support a universal childhood influenza vaccination policy. Epidemiol Rev 28 (2006) 41-46
69. Dombkowski K. School-based influenza vaccination program reduces influenza-related outcomes among household members. J Pediatr 151 (2007) 100
70. Mylius S.D., Hagenaars T.J., Lugnér A.K., and Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26 (2008) 3742-3749
71. Beutels P., Thiry N., and Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25 (2007) 1355-1367
72. Stein C., Kuchenmüller T., Hendrickx S., et al. The Global Burden of Disease Assessments-WHO is responsible?. PLoS Negl Trop Dis 1 (2007) e161